Veraxa plans to go public via SPAC at $1.64 billion valuation
.jpeg)
Veraxa plans to go public via SPAC at $1.64 billion valuation
Xlife Sciences’ portfolio company VERAXA Biotech AG, a biopharmaceutical company focused on next-generation cancer therapies, and Voyager Acquisition Corp., a special purpose acquisition company listed on Nasdaq, have entered a definitive business combination agreement. The proposed transaction values VERAXA Biotech AG at USD 1.64 billion with expected gross cash proceeds up to USD 253 million held in trust by Voyager Acquisition Corp.
VERAXA is a Swiss-based biopharmaceutical company advancing a premier drug discovery and development engine for ADCs and other novel antibody-based therapy concepts. The company originates from scientific discoveries made at the European Molecular Biology Laboratory (EMBL), Their proprietary technology, Bi-Targeted Antibody Cytotoxicity platform, enables a highly specific dual-marker approach, allowing the company to accelerate a pipeline of next-generation cancer therapies that have the potential to expand the therapeutic window of current solid tumor standard of care treatments through improved safety and efficacy profiles.
The company’s pipeline currently comprises nine discovery and development programs at various stages in development, including an active Phase 1 program in leukemia. The Company’s most advanced clinical asset, VX-A901, is developed as a novel therapeutic option for elderly AML (Acute myeloid leukemia) patients. Through a two-fold approach of pursuing both internal innovation and strategic partnerships, the Company anticipates having a robust pipeline by 2029, including three proprietary development programs in the clinic and a growing portfolio of licensed assets.
Post-SPAC valuation for VERAXA anticpated at USD 1.64 billion
VERAXA intends to list as a public company through a strategic merger with Voyager Acquisition Corp. (SPAC), a Cayman Islands exempted company and special purpose acquisition company targeting the healthcare sector. The proposed business combination would create a publicly traded, clinical-stage biopharmaceutical company.
Upon closing of the transaction, VERAXA will be listed on NASDAQ under the proposed ticker symbol “VERX”. The transaction values VERAXA, which is one of Xlife Sciences’ key portfolio businesses (current stake: ~18%), at approximately USD 1.3 billion (excluding trust funds). VERAXA’s shareholders will receive approximately 130 million shares of the combined company. Assuming a share price of USD 10.00 and no redemptions, the implied pro forma equity value of the combined entity will be approximately USD 1.64 billion. The business combination is expected to close in Q4 2025.
Furthermore, following the closing of the Business Combination, VERAXA anticipates access to approximately up to $253 million in cash held in trust by Voyager, prior to the payment of transaction costs of VERAXA and Voyager, and assuming no redemptions by Voyager’s public shareholders. Additionally, VERAXA is actively raising a crossover financing round from existing and new investors to provide VERAXA with sufficient capital for the next two years, not including various potential partnering and co-development opportunities.
Views: 41
Comments
You must be logged in to comment.
Latest Articals
-
.jpg)
A Chinese surgeon operated on a patient 8,000 kilometers away — and it was a complete success.
A Chinese surgeon operated on a patient 8,000 kilometers away — and it was a complete success.For the first time in the world, Dr. Zhang Xu was sitting in a room while a cancer patient was in Beijing. What connected them? A 5 G-powered surgical robot, which moved in real time with almost no latency.This wasn’t science fiction. This was telesurgery — performed live during a global medical conference, with robots mimicking Zhang’s every move from across continents.The delay? Just 135 milliseconds — faster than the blink of an eye.Zhang's team made history with this operation.And now? They've proven that when human skill and the power of connection come together, anything is possible.Because in the future of medicine, borders may not mean anything.Explanation:This article is about a very important and innovative medical development called "telesurgery".* Main idea: A Chinese surgeon (Dr. Zhang Shu) successfully operated on a cancer patient in...
-
.jpg)
Trump has no intention of engaging in a conversation with Musk due to their ongoing feud.
Trump has no intention of engaging in a conversation with Musk due to their ongoing feud. Now with Tesla, President Trump said. "We'll examine everything," the president said. It's a substantial sum. Trump was able to drive the red Tesla Model S, which he bought in March, after unveiling masked electric cars and anonymous White House officials. Musk, a social media platform called X, has strengthened comments made by others that have violated republican big beautiful calculations, resulting in a contribution of $36.2 trillion. He accurately responded to another user who criticized Congress, and Trump had to personally address the criticism. A more detailed advisor to mousek. The explanation for the white house's actions came the day after two individuals engaged in a public altercation, displaying a high level of animosity. I mainly have quietness during the conflict. On the one hand, investor James Fishbuck Muscas requested an apology. Trump has proposed the...
-
.jpg)
The war among
The war among President Donald Trump's biggest challenge at home comes from the judiciary of the country, not the opposition Democrats, who remain leaders and obstacles. The biggest stroke of the US president's trade policy was a federal court ruling over the past month, explaining the illegal tariffs he imposed on countries around the world. The government has secured a temporary debtor for the appeal court held by ruling, but the legal dispute has not ended. The appeal process must be completed, and the case can even go to the U.S. Supreme Court. Global financial markets welcomed the court's order on tariffs, which balances Trump. Trump was angry at the International Trade Court's decision, which was referred to as a false, political, "the toughest financial decision." His officials continued, accusing the judge of his transfer and accusing him of abuse of power in using the president's powers. In fact, according to...
-
.jpg)
A Neuralink Rival Just Tested a Brain Implant in a Person
A Neuralink Rival Just Tested a Brain Implant in a PersonBrain-computer-interface startup Paradromics today announced that surgeons successfully inserted the company’s brain implant into a patient and safely removed it after about 10 minutes.It’s a step toward longer trials of the device, dubbed Connexus. It’s also the latest commercial development in a growing field of companies, including Elon Musk’s Neuralink, aiming to connect people’s brains directly to computers.With the Connexus, Austin-based Paradromics is looking to restore speech and communication in people with spinal cord injury, stroke, or amyotrophic lateral sclerosis, also known as ALS. The device is designed to translate neural signals into synthesized speech, text, and cursor control. Paradromics, which was founded in 2015, has been testing its implant in sheep for the past few years. This is the first time it has used the device on a human patient.The procedure took place on May 14 at the University...
-
.jpg)
TSMC says US tariffs have some impact, but AI demand is robust
TSMC says US tariffs have some impact, but AI demand is robustHSINCHU, Taiwan, June 3 (Reuters) - Taiwan's TSMC (2330.TW) opens a new tab said on Tuesday that U.S. tariffs were having some impact on the company and had been discussed with Washington, but demand for artificial intelligence (AI) remains strong and continues to outpace supply.U.S. President Donald Trump's trade policies have created much uncertainty for the global chip industry and TSMC, the top producer of the world's most advanced semiconductors, whose customers include Apple (AAPL.O), opens a new tab and Nvidia (NVDA.O), opens a new tab .Chief Executive C.C. Wei, speaking at TSMC's annual shareholders meeting in the northern Taiwanese city of Hsinchu, said the company had not seen any changes in customer behaviour due to tariff uncertainty, and the situation might become clearer in the coming months."Tariffs do have some impact on TSMC, but not directly. That's because tariffs are imposed...
-
.jpg)
Qubit breakthrough could make it easier to build quantum computers
Qubit breakthrough could make it easier to build quantum computersQuantum computers that correct their errors usually require hundreds of thousands of qubits. Start-up Nord Quantique claims it can dramatically decrease that number, but many challenges remainA Canadian quantum computing start-up claims its new qubit will enable much smaller, cheaper, error-free quantum computers. But getting there will be a steep challenge.To correct its errors, a traditional computer saves duplicates of information in multiple places, a practice called redundancy. For quantum computers to achieve their redundancy, they typically require many additional quantum bits, or qubits – hundreds of thousands of them.Now, Julien Camirand Lemyre at Nord Quantique and his colleagues have created a qubit that they say will let them slash that number to mere hundreds. “The basic underlying idea behind our hardware is… having qubits that have intrinsic redundancy,” he says.There are several competing versions of qubits, such as tiny superconducting...